FULC vs GALT

Fulcrum Therapeutics, Inc. vs Galectin Therapeutics Inc. — Valuation Comparison 2026

FULC

Pharmaceutical Preparations
Fulcrum Therapeutics, Inc.
Quality
6.5
out of 10
Value Trap
18
SAFE
Price
$6.92
Last close
Models
9/13
Active
VS

GALT

Pharmaceutical Preparations
Galectin Therapeutics Inc.
Quality
3.7
out of 10
Value Trap
12
SAFE
Price
$2.52
Last close
Models
6/13
Active

Model-by-Model Comparison

ModelType FULC Fair ValueFULC Upside GALT Fair ValueGALT Upside
Bayesian DCF Intrinsic $2.10 -69.7% $0.71 -71.9%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $0.36 -94.5% $0.03 -99.0%
Dynamic NAV Asset-Based $•••.•• ••.•% $•••.•• ••.•%
PWERM Option-Based $6.05 -12.5% $4.13 +63.9%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for FULC vs GALT — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

FULC vs GALT — Which Stock Is More Undervalued?

FULC scores higher with a 6.5/10 quality rating vs GALT's 3.7/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Fulcrum Therapeutics, Inc. (FULC) and Galectin Therapeutics Inc. (GALT) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

FULC currently trades at $6.92 with a QOC of 6.5/10, while GALT trades at $2.52 with a QOC of 3.7/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).